FDA Talks Up Continuous Manufacturing, Offers Assistance
This article was originally published in The Gold Sheet
Executive Summary
It is time for drug makers to embrace continuous manufacturing methods, CDER Director Janet Woodcock and other FDA officials have been emphasizing in recent months. Now the agency is offering additional support to help manufacturers overcome regulatory barriers, real or perceived, and wean themselves from batch processes.
You may also be interested in...
FDA Highlights Advanced Drug Manufacturing Approaches In Budget Plan
FDA wants more companies to adopt continuous manufacturing, which could expand the US manufacturing base.
Will Continuous Manufacturing Mean Continuous Generic Delay? FDA Hears AAM's Warning
Association for Accessible Medicines calls for US FDA to guard against use of continuous manufacturing methods to protect brand drugs from batch-manufactured generic drugs that may be of lower but still acceptable quality. Then FDA approves first generic of a continuously manufactured drug.
Will Continuous Manufacturing Mean Continuous Generic Delay? FDA Hears AAM's Warning
Association for Accessible Medicines calls for US FDA to guard against use of continuous manufacturing methods to protect brand drugs from batch-manufactured generic drugs that may be of lower but still acceptable quality. Then FDA approves first generic of a continuously manufactured drug.